CN1946740A - 抗人腱生蛋白单克隆抗体 - Google Patents
抗人腱生蛋白单克隆抗体 Download PDFInfo
- Publication number
- CN1946740A CN1946740A CNA2005800061324A CN200580006132A CN1946740A CN 1946740 A CN1946740 A CN 1946740A CN A2005800061324 A CNA2005800061324 A CN A2005800061324A CN 200580006132 A CN200580006132 A CN 200580006132A CN 1946740 A CN1946740 A CN 1946740A
- Authority
- CN
- China
- Prior art keywords
- antibody
- derivative
- fragment
- biotinylation
- biotinylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (34)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITRM2004A000105 | 2004-02-27 | ||
IT000105A ITRM20040105A1 (it) | 2004-02-27 | 2004-02-27 | Anticorpo monoclonale antitenascina umana. |
PCT/IT2005/000078 WO2005082938A2 (en) | 2004-02-27 | 2005-02-16 | Anti-human tenascin monoclonal antibody |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1946740A true CN1946740A (zh) | 2007-04-11 |
CN1946740B CN1946740B (zh) | 2012-09-05 |
Family
ID=34897820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800061324A Expired - Fee Related CN1946740B (zh) | 2004-02-27 | 2005-02-16 | 抗人腱生蛋白单克隆抗体 |
Country Status (16)
Country | Link |
---|---|
US (1) | US7989171B2 (zh) |
EP (1) | EP1718678B1 (zh) |
JP (1) | JP5191036B2 (zh) |
KR (1) | KR101266389B1 (zh) |
CN (1) | CN1946740B (zh) |
AR (1) | AR047819A1 (zh) |
AU (1) | AU2005217237B2 (zh) |
BR (1) | BRPI0508082A8 (zh) |
CA (1) | CA2558718C (zh) |
ES (1) | ES2654065T3 (zh) |
HK (1) | HK1100848A1 (zh) |
IT (1) | ITRM20040105A1 (zh) |
MX (1) | MXPA06009674A (zh) |
PL (1) | PL1718678T3 (zh) |
PT (1) | PT1718678T (zh) |
WO (1) | WO2005082938A2 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109952312A (zh) * | 2016-09-29 | 2019-06-28 | 纳塞恩特公司 | 生腱蛋白表位和其抗体 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
US8404637B2 (en) | 2005-02-11 | 2013-03-26 | Amylin Pharmaceuticals, Llc | GIP analog and hybrid polypeptides with selectable properties |
JP2012031084A (ja) * | 2010-07-29 | 2012-02-16 | Tokyo Univ Of Science | 抗腫瘍剤 |
WO2014113459A1 (en) * | 2013-01-15 | 2014-07-24 | Duke University | Hiv-1 neutralizing factor |
US20160097771A1 (en) * | 2013-05-21 | 2016-04-07 | NX Pharmagen | Use of tenascin-c as an extracellular marker of tumor-derived microparticles |
WO2023240135A2 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5634076A (en) * | 1994-10-04 | 1997-05-27 | Analog Devices, Inc. | DMA controller responsive to transition of a request signal between first state and second state and maintaining of second state for controlling data transfer |
US6014709A (en) * | 1997-11-05 | 2000-01-11 | Unisys Corporation | Message flow protocol for avoiding deadlocks |
US6335014B1 (en) * | 1998-06-17 | 2002-01-01 | The Institute Of Physical And Chemical Research | Medicament for suppressing cancer metastasis |
US6521593B1 (en) * | 1999-02-01 | 2003-02-18 | Childrens Hospital Los Angeles | Methods for inhibiting brain tumor growth |
WO2000066628A1 (en) * | 1999-05-01 | 2000-11-09 | University Of Medicine And Dentistry Of New Jersey | Neurite outgrowth and guidance by tenascin-c |
US7058750B1 (en) * | 2000-05-10 | 2006-06-06 | Intel Corporation | Scalable distributed memory and I/O multiprocessor system |
JP3646159B2 (ja) * | 2001-02-08 | 2005-05-11 | 国立大学法人三重大学 | 抗テネイシンcモノクローナル抗体及び当該抗体を産生するハイブリドーマ |
ITRM20010079A1 (it) | 2001-02-16 | 2002-08-16 | Sigma Tau Ind Farmaceuti | Amminoderivati della biotina e loro coniugati con chelanti macrociclici. |
US7438908B2 (en) * | 2002-02-26 | 2008-10-21 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Anti-human tenascin monoclonal antibody |
ITRM20020128A1 (it) * | 2002-03-08 | 2003-09-08 | Sigma Tau Ind Farmaceuti | Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting". |
-
2004
- 2004-02-27 IT IT000105A patent/ITRM20040105A1/it unknown
-
2005
- 2005-02-16 EP EP05718988.8A patent/EP1718678B1/en active Active
- 2005-02-16 BR BRPI0508082A patent/BRPI0508082A8/pt not_active IP Right Cessation
- 2005-02-16 CA CA2558718A patent/CA2558718C/en not_active Expired - Fee Related
- 2005-02-16 WO PCT/IT2005/000078 patent/WO2005082938A2/en active Application Filing
- 2005-02-16 PL PL05718988T patent/PL1718678T3/pl unknown
- 2005-02-16 ES ES05718988.8T patent/ES2654065T3/es active Active
- 2005-02-16 JP JP2007500356A patent/JP5191036B2/ja not_active Expired - Fee Related
- 2005-02-16 CN CN2005800061324A patent/CN1946740B/zh not_active Expired - Fee Related
- 2005-02-16 AU AU2005217237A patent/AU2005217237B2/en not_active Ceased
- 2005-02-16 PT PT57189888T patent/PT1718678T/pt unknown
- 2005-02-16 US US10/590,936 patent/US7989171B2/en not_active Expired - Fee Related
- 2005-02-16 MX MXPA06009674A patent/MXPA06009674A/es active IP Right Grant
- 2005-02-24 AR ARP050100671A patent/AR047819A1/es not_active Application Discontinuation
-
2006
- 2006-09-27 KR KR1020067020062A patent/KR101266389B1/ko active IP Right Grant
-
2007
- 2007-08-06 HK HK07108522.3A patent/HK1100848A1/xx not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109952312A (zh) * | 2016-09-29 | 2019-06-28 | 纳塞恩特公司 | 生腱蛋白表位和其抗体 |
Also Published As
Publication number | Publication date |
---|---|
JP2008506355A (ja) | 2008-03-06 |
AU2005217237B2 (en) | 2011-12-22 |
KR101266389B1 (ko) | 2013-05-28 |
KR20070002029A (ko) | 2007-01-04 |
WO2005082938A3 (en) | 2005-12-15 |
AR047819A1 (es) | 2006-02-22 |
PT1718678T (pt) | 2017-12-29 |
US20100297003A1 (en) | 2010-11-25 |
MXPA06009674A (es) | 2007-03-21 |
BRPI0508082A (pt) | 2007-07-17 |
EP1718678A2 (en) | 2006-11-08 |
CA2558718C (en) | 2015-01-13 |
BRPI0508082A8 (pt) | 2017-12-26 |
CN1946740B (zh) | 2012-09-05 |
ITRM20040105A1 (it) | 2004-05-27 |
EP1718678B1 (en) | 2017-10-11 |
HK1100848A1 (en) | 2007-09-28 |
JP5191036B2 (ja) | 2013-04-24 |
US7989171B2 (en) | 2011-08-02 |
ES2654065T3 (es) | 2018-02-12 |
PL1718678T3 (pl) | 2018-05-30 |
CA2558718A1 (en) | 2005-09-09 |
AU2005217237A1 (en) | 2005-09-09 |
WO2005082938A2 (en) | 2005-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1317303C (zh) | 抗人腱生蛋白单克隆抗体 | |
CN1187374C (zh) | 人源化的特异于人4-1bb的抗体和含有它的药物组合物 | |
CN1267452C (zh) | 单克隆抗体、抗原和恶性疾病的诊断和治疗 | |
CN1235911C (zh) | 多细胞因子-抗体复合物 | |
CN1268645C (zh) | 含有抗-fc受体结合剂的治疗化合物 | |
CN1606453A (zh) | Cripto阻断抗体及其用途 | |
CN1203603A (zh) | 由抗-Fc受体抗体组成的治疗化合物 | |
CN1105728C (zh) | 用于治疗il4介导疾病的重组il4抗体 | |
CN1898264A (zh) | 用新的抗il13单克隆抗体治疗癌症 | |
CN1620468A (zh) | 新的抗igf-ir抗体及其应用 | |
CN1946740A (zh) | 抗人腱生蛋白单克隆抗体 | |
CN1277632A (zh) | 天然人源化抗体 | |
CN1155904A (zh) | Lag-3蛋白的可溶性多肽组分;生产方法、治疗组合物、抗独特型抗体 | |
CN1308676A (zh) | 抗cd23抗体、抗cd23抗体衍生物及其治疗性应用 | |
CN1703243A (zh) | 针对erb-b1受体的药物组合物 | |
CN1662558A (zh) | 人cd22特异性抗体及其治疗和诊断应用 | |
CN1671837A (zh) | 抗***受体(igfr)的人源中和抗体 | |
CN1522264A (zh) | 抗cd40单克隆抗体 | |
CN1076966A (zh) | 抗人白细胞介素-4的人性化单克隆抗体的克隆和表达 | |
CN1277614A (zh) | ***珠蛋白,一种***特异性乳腺癌分泌蛋白 | |
CN1294517A (zh) | 具有合成可变区和修饰特异性的免疫球蛋白分子 | |
CN1222162A (zh) | 突变的无激活作用的IgG2结构域和***该结构域的抗CD3抗体 | |
CN1422333A (zh) | 诱导细胞凋亡的多肽 | |
CN1345246A (zh) | 预防或治疗癌症及与癌症相关的骨损失的组合物和方法 | |
CN1905899A (zh) | EphA2激动性单克隆抗体及其使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1100848 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. Free format text: FORMER OWNER: TECNOGEN S. P. A. Effective date: 20130308 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20130308 Address after: Rome Italy Patentee after: Sigma-Tau Industrie Farmaceutiche Riunite S. P. A. Address before: Pianardi Monteville, Italy Patentee before: Tecnogen S. P. A. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1100848 Country of ref document: HK |
|
TR01 | Transfer of patent right |
Effective date of registration: 20171207 Address after: Milan Italy Patentee after: Alpha Sigg Ma Co. Address before: Rome Italy Patentee before: Sigma-Tau Industrie Farmaceutiche Riunite S. P. A. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120905 Termination date: 20200216 |
|
CF01 | Termination of patent right due to non-payment of annual fee |